Sarepta Therapeutics made a surprising announcement on Monday evening, revealing that it will be pausing all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy. This decision comes in response to a request from the Food and Drug Administration (FDA), which the company had initially rejected when it was issued on Friday.
According to Sarepta, shipments of Elevidys will come to a halt by the close of business on Tuesday evening. This move marks a significant shift for the company, as it had initially resisted the FDA’s request before ultimately complying with it.
The decision to pause shipments of Elevidys raises questions about the future of the gene therapy and its potential impact on patients with Duchenne muscular dystrophy. Sarepta had high hopes for Elevidys, which was developed to address the underlying genetic cause of the disease and potentially provide a much-needed treatment option for patients and their families.
In light of this development, stakeholders in the biotech and healthcare industries will be closely monitoring the situation to see how it unfolds. The pause in shipments raises concerns about the regulatory hurdles that Sarepta may be facing with Elevidys and the implications for the company’s overall drug development pipeline.
For more updates on this story and other developments in the biotech sector, subscribe to STAT+ for exclusive access to in-depth analysis and coverage. Stay tuned for further updates on Sarepta Therapeutics and the future of Elevidys as more information becomes available.
